Pertussis prevention and treatment: a call for wider access to azithromycin

被引：3

作者：

Bowen, Asha C.

Ferson, Mark J. ^{[3
]}

Graudins, Linda V. ^{[1
,2
]}

Palasanthiran, Pamela ^{[1
]}

机构：

[1] Sydney Childrens Hosp, Paediat Therapeut Program, Sydney, NSW, Australia

[2] Univ New S Wales, Paediat Therapeut Program, Sydney, NSW, Australia

[3] S Eastern Sydney & Illawarra Hlth, Publ Hlth Unit, Sydney, NSW, Australia

来源：

MEDICAL JOURNAL OF AUSTRALIA | 2009年 / 190卷 / 07期

关键词：

D O I：

10.5694/j.1326-5377.2009.tb02455.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Azithromycin is recommended as the first-line antibiotic for the prophylaxis and treatment of pertussis, a common vaccine-preventable communicable disease. Azithromycin is better tolerated than other macrolide antibiotics. Access to azithromycin is limited, as the product information and the Pharmaceutical Benefits Scheme do not include azithromycin for pertussis. Issues regarding access to azithromycin are highlighted in a case report of pertussis exposure in a tertiary paediatric hospital.

引用

页码：388 / 389

页数：2

共 11 条

[1] Antibiotics for whooping cough (pertussis) (Withdrawn Paper. 2007, atr. no. CD004404) [J].